Xeris reports ‘positive’ data from study of ready-to-use glucagon rescue pen

Xeris Pharmaceuticals announced the presentation of positive results from two of its Phase 3 clinical studies on its investigational ready-to-use, room-temperature stable liquid glucagon rescue pen during oral and poster sessions at the American Diabetes Association’s 78th Scientific Sessions, June 22-26, 2018. The data presentations highlight the efficacy and safety data from studies of the Xeris ready-to-use glucagon rescue pen in treating severe hypoglycemia in adults and children with type 1 diabetes, as compared to the currently marketed Glucagon Emergency Kit. In addition to the Phase 3 study results presented at the ADA conference, Xeris also generated positive data from an additional Phase 3 cross-over study of the Xeris rescue pen among adults with type 1 diabetes. In that study, all participants treated with the Xeris rescue pen achieved plasma glucose of greater than70 mg/dL or greater than or equal to 20 mg/dl increase within 30 minutes of injection. There were no reported significant adverse events and adverse events were generally mild to moderate in severity, with the most common being nausea and vomiting. “Together, the positive data from multiple studies demonstrate that our ready-to-use glucagon rescue pen has the potential to be a well-tolerated and functionally effective alternative to treat severe hypoglycemia among both adults and children with diabetes,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals. “We look forward to advancing our program with the goal of introducing a valued new emergency intervention for the diabetes community.”

https://bit.ly/2tCf6R3